The Burden of Multiple Myeloma on Patients and Caregivers Quality of Life: a Canadian Real-World Study
NCT ID: NCT06610045
Last Updated: 2025-03-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
400 participants
OBSERVATIONAL
2024-10-15
2025-03-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Factors Associated With Health-related Quality of Life and Social Participation of Patients With Multiple Myeloma and Their Caregivers
NCT07014865
Impacts on Health Outcomes and Resources Utilization of Hospital-at-home for Elderly Patients With Multiple Myeloma
NCT03490084
Patient and Care Partner Experiences Living With Multiple Myeloma (PaCE-MM)
NCT05276622
Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma
NCT06485076
Effects of Early Palliative Care Integration on Patients With Newly Diagnosed Multiple Myeloma
NCT04248244
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
An e-mail will be sent to 600 patients and 200 caregivers randomly selected to invited them to participate in the survey. Interested participants will be invited to visit the Participant Portal on the PROxy website (https://periproxy.com/en), to sign the informed consent form and complete online questionnaires. Upon request, paper-based documents (i.e., informed consent form and questionnaires) can also be sent by mail. The following questionnaires will be used:
Patients
* Patient Information Questionnaire (i.e., baseline characteristics)
* EORTC QLQ-C30
* EORTC QLQ-MY20
* EQ-5D-5L
* ESAS-R
* Patients Perspective
Caregivers
* Caregiver Information Questionnaire (i.e., baseline characteristics)
* CarGOQoL
* Caregivers Perspective
If the sample size (i.e., 300 patients and 100 caregivers) is not reached one month after the first e-mail, an invitation e-mail will be sent to an additional 600 eligible patients and/or 200 caregivers randomly selected. This scheme of participant identification will be performed until the sample size is reached.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with multiple myeloma
Patients with multiple myeloma member of Myeloma Canada database
No intervention
No specific intervention is assess in this study.
Caregivers of patients with myeloma
Caregiver of a multiple myeloma patient member of Myeloma Canada database
No intervention
No specific intervention is assess in this study.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No intervention
No specific intervention is assess in this study.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Part of the Myeloma Canada database;
1. Identified as a patient with MM or
2. Identified as a current caregiver of a patient with MM at the time of participation.
3. Ability to read and understand English or French;
4. Signature of informed consent form (ICF).
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
PeriPharm
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
PROxy Network, an initiative of PeriPharm inc.
Montreal, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PROxy202301
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.